35 citations
,
November 2022 in “The Journal of Dermatology” Alopecia areata is becoming more common in Japan, with a need for better treatments, especially for severe and pediatric cases.
July 2024 in “JAAD Case Reports” Ruxolitinib helped regrow hair in a woman with a blood disorder and complete hair loss.
20 citations
,
September 2003 in “Journal of Investigative Dermatology” Targeting MIG and MCP-1 may help treat inflammation in alopecia areata.
248 citations
,
August 2015 in “Pharmacological Research” Vaccines are generally safe, but rare autoimmune reactions can occur, often influenced by genetics.
January 2018 in “Indian Dermatology Online Journal” DM and AA may share a common cause.
15 citations
,
January 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.
13 citations
,
February 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.
10 citations
,
June 2019 in “Dermatologic therapy” DPCP alone is more effective and safer for treating chronic extensive alopecia areata than combining it with anthralin.
January 2025 in “Dermatologic Therapy” Baricitinib works better for alopecia areata in patients not previously treated with tofacitinib.
5 citations
,
October 2021 in “Clinical, cosmetic and investigational dermatology” Japanese patients with alopecia areata often have a higher BMI and consume more vitamin C, fruit, and retinol, which may affect their condition's development or severity.
December 2025 in “Cosmetics” Gut bacteria differences could help diagnose and treat alopecia areata.
Tofacitinib effectively regrows hair in alopecia universalis triggered by a virus.
1 citations
,
December 2025 in “Photodermatology Photoimmunology & Photomedicine” Phototherapy effectively treats certain alopecia areata types, especially if started early.
December 2024 in “Journal of Clinical Medicine” Minoxidil shows promise for alopecia areata, but more research is needed before it can be recommended as a primary treatment.
August 2023 in “Dermatology and Therapy” Experts recommend personalized treatment plans for best outcomes in managing Alopecia Areata.
June 2024 in “Australasian Journal of Dermatology” Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.
January 2026 in “Nutrients” Low vitamin D may increase autoimmune thyroid disease risk, but its treatment effects are unclear.
March 2026 in “JID Innovations” Aire mutation reduces alopecia areata, while Notch4 mutation prevents it in mice.
31 citations
,
July 2023 in “Nutrients” Vitamin D may help reduce thyroid antibodies and improve thyroid function in Hashimoto's Thyroiditis.
24 citations
,
January 2018 in “International Journal of Trichology” Tofacitinib helped regrow hair in patients with alopecia, with few side effects.
2 citations
,
April 2025 in “Biologics” Dupilumab and ustekinumab are promising treatments for alopecia areata, showing significant hair regrowth.
October 2025 in “Cosmetics” Genetic insights can lead to personalized treatments for acne, androgenetic alopecia, and alopecia areata.
September 2025 in “Immunological Reviews” The skin can independently form immune responses through special structures, offering new ways to treat skin diseases.
March 2024 in “Nutrients” Alopecia Areata is linked to specific gut bacteria and metabolites, indicating a complex gut microbiome.
6 citations
,
October 2024 in “Journal of Family Medicine and Primary Care” Primary care doctors need to monitor JAK and TYK-2 inhibitors carefully for skin conditions.
355 citations
,
January 2017 in “Journal of the American Academy of Dermatology” JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.
40 citations
,
June 2021 in “Clinical, cosmetic and investigational dermatology” JAK inhibitors show promise in effectively treating hair loss from alopecia areata.
1 citations
,
December 2023 in “Molecules/Molecules online/Molecules annual” JAK inhibitors show promise for treating various skin diseases.
Ritlecitinib helps reduce inflammation and promote hair regrowth in alopecia areata, especially in patchy-type cases.
September 2025 in “International Journal of Molecular Sciences” Deucravacitinib may help treat various immune diseases beyond psoriasis, but more research is needed.